Coverage
HFX SCS Therapy is covered by nearly all major insurance plans, including Medicare, as a late or last resort therapy for chronic intractable back and leg pain. Payers continue to add painful diabetic neuropathy (PDN) as a covered indication for HFX SCS therapy based upon Nevro’s published level one Randomized Controlled Trial (RCT) evidence for PDN.
Most payers require prior authorization for SCS to show that the patient is refractory to conventional medical management (CMM). Nevro’s Market Access team can provide up-to-date spinal cord stimulation coverage policies for any insurance plan. These policies highlight the covered indications and specific documentation requirements. Please reach out to Market.Access@nevro.com for details.